CLINICAL STUDY

Free thyroxine is an independent predictor of subcutaneous fat in euthyroid individuals

Maria Alevizaki 1,2, Katerina Saltiki 1,2, Paraskevi Voidonikola 3, Emily Mantzou 1, Christos Papamichael 3 and Kimon Stamatelopoulos 4

1Endocrine Unit, Department of Endocrinology and Metabolism, 'Egewidion' Hospital, Athens University School of Medicine, 18, Papadomanopoulo Avenue, 11528 Athens, Greece, 2Endocrine Unit, Department of Medical Therapeutics, Alexandra Hospital, Athens University School of Medicine, 80 Vass Sofias Avenue, 11528 Athens, Greece and 3Vascular Laboratory, Department of Medical Therapeutics, Alexandra Hospital, Athens University School of Medicine, 80 Vass Sofias Avenue, 11528 Athens, Greece

(Correspondence should be addressed to M Alevizaki; Email: mani@otenet.gr)

Abstract

Objective: Thyroid function parameters have been associated with obesity, but associations with the type of adiposity have not been examined. We used ultrasound (US) to assess regional adiposity and investigated associations of thyroid function with parameters of central obesity.

Design: Cross-sectional study.

Methods: A total of 303 apparently healthy individuals (age 42.9 ± 8.8, body mass index (BMI) 19.0–43.3, median 26.2 kg/m², 181 women) were examined for indices of the metabolic syndrome. BMI, waist and hip circumference, abdominal subcutaneous fat (SF), and preperitoneal fat (PF) layer was estimated. TSH, free thyroxine (fT4), triiodothyronine (T3), thyroid autoantibodies, insulin, glucose, and lipid levels were measured. Subjects receiving T4 (9.2%) were excluded.

Results: SF and SF/PF ratio were inversely correlated with fT4 levels (r = −0.169, P = 0.023, r = −0.193, P = 0.009 respectively). In multivariate analysis, fT4 was a predictor of SF and SF/PF independently of age, sex, and smoking. SF correlated with TSH levels (r = 0.149, P = 0.037), PF and SF were positively associated with T3 levels (r = 0.245, P = 0.004 and r = 0.189, P = 0.019 respectively). T3 levels were positively associated with BMI (r = 0.257, P = 0.0004), waist perimeter (r = 0.324, P < 0.0001), and waist-to-hip ratio (WHR; r = 0.363, P < 0.0001). The T3/fT4 ratio was positively correlated with SF (r = 0.182, P = 0.028), WHR (r = 0.267, P = 0.0003), and BMI (r = 0.146, P = 0.043).

Conclusions: Increasing SF accumulation as assessed by US is associated with lower T3 and higher TSH levels among euthyroid slightly overweight individuals. These associations indicate that subtle variation in thyroid function may participate in regional adiposity.

European Journal of Endocrinology 161 459–465

Introduction

Thyroid function has been associated with obesity in several reports, but this relationship is not etiologically clear (1). Overt hypothyroidism may be associated with increased body weight (2) as well as with various adverse cardiovascular effects. Similarly, subclinical hypothyroidism has also been associated with higher body mass index (BMI), especially in older women (3), but this finding is not consistent (4).

Furthermore, even in the normal population, there are studies that have reported associations between thyroid function parameters such as TSH and thyroid hormone levels, within the normal range, and changes in BMI (5), weight (6), and fat distribution (7). A large population study showed that TSH levels were positively and free thyroxine (fT4) levels negatively associated with BMI (5). In two large population studies, among non-smokers. BMI was also positively correlated with TSH (8) and inversely with fT4 (9). Finally, TSH was correlated with BMI in older females (10). However, these results have not been confirmed by all investigators; Manji et al. reported no associations of TSH or fT4 levels with BMI in euthyroid individuals (11).

The association of thyroid function parameters with fat distribution has not been studied in detail. De Pergola et al. (7) reported that central fat accumulation, as assessed by waist circumference measurement, was positively and independently associated with TSH and free triiodothyronine (fT3) levels in overweight and obese euthyroid women.

Thyroid function parameters even within the normal range have also been associated with alterations in metabolic and cardiovascular parameters such as arterial pressure, endothelial function and coronary heart disease (4, 12–14). Moreover, even slightly
impaired thyroid function might be associated with dyslipidemia and insulin resistance (13).

It is well known that adipose tissue and especially visceral fat is implicated in the pathogenesis of the metabolic syndrome (MS). Subjects with increased central fat distribution are at higher risk for the development of cardiometabolic disease (15). Visceral and subcutaneous fat (SF) expresses thyroid hormone receptors (16–19) as well as TSH receptors that may also directly influence various functions of adipose cells (20). However, it is not known whether the type of adiposity could be implicated in the associations of thyroid function parameters with obesity.

The aim of our study was to investigate in apparently healthy individuals possible associations of thyroid function with measurements of central and peripheral obesity and parameters of the MS. For this purpose we used ultrasound (US), a reliable low-cost method, to assess regional adiposity.

**Subjects and methods**

We studied 303 apparently healthy individuals (181 women, 122 men, mean age 42.9 ± 8.8, BMI 19.0–43.3, median 26.2 kg/m²) who were examined for indices of the MS. All subjects were attending a preventive medicine program that offered investigation for the presence of unrecognized MS in the outpatients clinic of our hospital over a period of 11 months. The inclusion criteria of our study were the absence of a history of diabetes (previously diagnosed according to the American Diabetes Association criteria), as well as the absence of overt cardiovascular or other systemic disease. A total of 41.1% were current smokers or had recently (≤ 6 months) ceased smoking. Thyroid function tests (FT₄, TSH, T₃, antiTG autoantibodies and antiTPO autoantibodies) were included in the protocol.

Subjects receiving T₄ or drugs possibly affecting thyroid function (such as lithium, amiodarone, interferon-gamma) or circulating free thyroid hormone levels (such as continuous treatment with high doses of salicylate or non-steroid anti-inflammatory drugs) were excluded from the analysis (9.2%, n = 28), so the population finally analyzed included 275 subjects (163 women and 112 men). The study was approved by the institutional Ethics Committee and all subjects gave their informed consent.

Height and weight were measured with subjects wearing indoor clothes without shoes. BMI was calculated according to the formula weight (kg)/height (m²). Waist and hip perimeter (cm) measurements were also performed. WHR was used to evaluate fat distribution. Arterial pressure was measured in a sitting position using a standard mercury sphygmomanometer.

Classical predisposing risk factors for cardiovascular disease, MS (arterial hypertension, dyslipidemia, smoking etc.), and current drug therapy were also recorded. Ninety-one (55.8%) of women out of the total participating in the study were premenopausal. The presence of the MS was defined using the ATP III criteria, i.e. the presence of any three of the following metabolic traits: abdominal obesity (waist circumference >102 cm for men and >88 cm for women); triglycerides (≥ 150 mg/dl, high-density lipoprotein (HDL) <40 mg/dl for men and <50 mg/dl for women); blood pressure (≥ 130/85 mmHg); and fasting glucose (≥ 100 mg/dl; 5.55 mmol/l) (21).

Fasting blood samples were obtained by venipuncture between 0800 and 0900 h. Serum TSH, FT₄ and T₃ were measured using chemiluminescent immunometric assays with the DPC Immulite 2000 (Siemens, Gwynedd, UK). Serum anti-thyroid antibodies (antiTPO, antiTG) analysis was performed by RIA using the reagents Brahms DINO test (BRAHMS Diagnostica GmbH, Berlin, Germany). The reference ranges were: TSH 0.36–4 mU/l; T₄ 9–26 pmol/l; T₃ 1.1–2.9 nmol/l; antiTPO <60 IU/ml; and antiTG <60 IU/ml. The T₃/T₄ ratio was calculated as an index of the activity of peripheral 5’-deiodinase.

The levels of glucose, total cholesterol, HDL, low-density lipoprotein (LDL), triglycerides, and uric acid were measured immediately (using an automated analyzer, Integra 400, Roche). Insulin levels (in specimens kept frozen at −20 °C until analysis was performed by IRMA, Biosource Europe SA, Nivelles, Belgium) were also estimated. Basal insulin resistance index (homeostasis model assessment-insulin-resistance-index, HOMA-IR) was calculated according to the formula: insulin resistance = FI×G/22.5, where FI=fasting insulin (µU/ml) and G=fasting glucose (mmol/l).

Abdominal SF and preperitoneal fat (PF) layers were estimated by B-mode US imaging (US, 7.0 MHz, linear array transducer, Acuson 128 XP, Mountain View, CA, USA). The measurements that were obtained were the following: minimum SF, defined as the minimum distance from the skin to linea alba, and maximum PF, defined as the maximum distance from linea alba to the interior surface of the liver. The ratio of SF to PF layer (S/P) was then calculated. Coefficient of variation of these measurements obtained by the same investigator was 6.8% and was quite similar to that previously reported (22). The measurement of the maximum PF layer that highly correlated with visceral fat has been previously shown (22). US is considered a reliable method for the assessment of regional adiposity compared to other diagnostic procedures such as computed tomography, dual energy x-ray absorptiometry (DEXA), magnetic resonance imaging and at the same time it is a simpler and inexpensive procedure (22–25).
Statistical analysis
Statistical analysis was done using the SPSS statistical package. All descriptive data are presented as mean ± s.d. Pearson’s correlation coefficient was used to investigate correlations between continuous variables. Multiple regression analysis was performed to investigate the simultaneous effect of different variables on the adiposity parameters. In the initial simple regression analysis, a threshold of \( P < 0.05 \) was used to identify candidate variables for inclusion in the final model. The multiple regression analyses were performed using the enter procedure. All covariates included in the final models were tested for interactions with each other. Because the tolerance values for each covariate were > 0.5, no correction for the co-linearity of data were necessary. Student’s \( t \)-test was used to compare mean values between groups where the distribution was normal.

Results
TSH range was 0.18–5.9, median 1.4 mU/l; \( fT_4 \) range was 11.5–25.9, median 17.4 pmol/l. \( T_3 \) range was 0.72–1.7, median 1.17 nmol/l. Eight subjects had TSH levels between 0.18 and 0.35 mU/l and were considered as having subclinical hyperthyroidism, while seven subjects had TSH levels between 4.1 and 5.9 mU/l and were considered as having subclinical hypothyroidism. The clinical and biochemical characteristics of the population are shown in Table 1.

SF was inversely correlated with \( fT_4 \) levels \((r = -0.168, \ P = 0.017) \); the SF/PF ratio was also inversely, rather weakly correlated with \( fT_4 \) levels \((r = -0.194, \ P = 0.006; \text{Fig. 1}) \). These associations remained significant only when subjects with BMI \( \geq 25 \) were analyzed \((r = -0.25, \ P = 0.009 \text{ and } r = -0.21, \ P = 0.026 \text{ respectively}) \), while they were not significant in the subjects with BMI < 25. When only male subjects were analyzed, SF and SF/PF were inversely correlated with \( fT_4 \) levels \((r = -0.247, \ P = 0.027 \text{ and } r = -0.2193, \ P = 0.05 \text{ respectively}) \). When only female subjects were examined there was no significant association between SF and \( fT_4 \) levels while there was a weak negative association between the ratio SF/PF and \( fT_4 \) levels \((r = -0.14, \ P = 0.14 \text{ and } r = -0.19, \ P = 0.044 \text{ respectively}) \).

By multivariate regression analysis, \( fT_4 \) levels among age, smoking, HOMA-IR, and gender were a significant independent predictor of SF (Table 2). \( fT_4 \) was also an independent predictor of the ratio SF/PF (Table 2).

Table 1 Characteristics of the studied population (n=275).

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Mean ± s.d.</th>
<th>Median</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>46.71 ± 8.9</td>
<td>48.00</td>
<td>34.3–52.2</td>
</tr>
<tr>
<td>Gender (female) n (%)</td>
<td>163 (59.3%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI (kg)</td>
<td>26.9 ± 4.77</td>
<td>26.21</td>
<td>18.0–42.3</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>77.02 ± 16.5</td>
<td>75.00</td>
<td>49–125</td>
</tr>
<tr>
<td>Waist perimeter (cm)</td>
<td>90.5 ± 14.8</td>
<td>90.00</td>
<td>53–130</td>
</tr>
<tr>
<td>Waist-to-hip ratio</td>
<td>0.87 ± 0.13</td>
<td>0.87</td>
<td>0.5–1.4</td>
</tr>
<tr>
<td>Pre-peritoneal fat layer (mm)</td>
<td>12.16 ± 4.6</td>
<td>12.10</td>
<td>0.8–30.5</td>
</tr>
<tr>
<td>Subcutaneous fat layer (mm)</td>
<td>12.05 ± 5.38</td>
<td>11.25</td>
<td>0.7–32</td>
</tr>
<tr>
<td>Metabolic syndrome n (%)</td>
<td>37 (13.4%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TSH (mU/l)</td>
<td>1.56 ± 0.94</td>
<td>1.40</td>
<td>0.18–5.9</td>
</tr>
<tr>
<td>Free T4 (pmol/l)</td>
<td>17.57 ± 2.5</td>
<td>17.40</td>
<td>11.5–25.9</td>
</tr>
<tr>
<td>T3 (mmol/l)</td>
<td>1.18 ± 0.18</td>
<td>1.17</td>
<td>0.72–1.71</td>
</tr>
<tr>
<td>HOMA-IR index</td>
<td>1.85 ± 1.4</td>
<td>1.46</td>
<td>0.4–11.0</td>
</tr>
<tr>
<td>Total cholesterol (mg/dl)</td>
<td>209.3 ± 40.1</td>
<td>208.0</td>
<td>123–372</td>
</tr>
<tr>
<td>(mmol/l)</td>
<td>5.41 ± 1.03</td>
<td>5.38</td>
<td>3.18–9.60</td>
</tr>
<tr>
<td>HDL (mg/dl)</td>
<td>59.26 ± 15.8</td>
<td>58.0</td>
<td>22.0–120.0</td>
</tr>
<tr>
<td>(mmol/l)</td>
<td>1.53 ± 0.40</td>
<td>1.50</td>
<td>0.57–3.10</td>
</tr>
<tr>
<td>LDL (mg/dl)</td>
<td>145.24 ± 38.4</td>
<td>141.0</td>
<td>71.0–233.0</td>
</tr>
<tr>
<td>(mmol/l)</td>
<td>3.75 ± 0.99</td>
<td>3.64</td>
<td>1.83–6.0</td>
</tr>
</tbody>
</table>

Figure 1 Association of free \( T_4 \) with subcutaneous fat thickness \((r = -0.169, \ P = 0.023) \) and subcutaneous/preperitoneal fat ratio \((r = -0.193, \ P = 0.009) \) in euthyroid apparently healthy individuals.
Thus, for a change of 1 pmol/l in $fT_4$, a decrease of 0.414 mm and 0.051 units is expected in the SF and in the ratio SF/PF respectively.

In the univariate analysis SF showed a positive association with TSH levels in all subjects (Pearson’s correlation, $r=0.149$, $P=0.037$) as well as in those with BMI $\geq 25$ ($r=0.19$, $P=0.035$); however, this association was no longer significant in the multivariate analysis when other confounding factors were taken into account (age, gender, smoking, HOMA-IR).

SF was positively associated with WHR ($r=0.213$, $P=0.003$), HOMA-IR ($r=0.346$, $P<0.001$), total cholesterol levels ($r=0.16$, $P=0.022$), LDL levels ($r=0.154$, $P=0.026$), and triglyceride levels ($r=0.1611$, $P=0.020$).

PF was also associated with WHR ($r=0.434$, $P<0.0001$), HOMA-IR ($r=0.2519$, $P=0.0003$), and lipid levels. There was no association between PF layer thickness and $fT_4$ or TSH levels.

There were no significant associations of $fT_4$ and TSH levels with waist perimeter, WHR or BMI. No association between $fT_4$ and HOMA-IR or lipid levels was found. Higher TSH levels were associated with higher total cholesterol, LDL levels and HOMA-IR ($r=0.16$, $P=0.006$, $r=0.15$, $P=0.008$, and $r=0.124$, $P=0.035$ respectively).

SF and PF were positively associated with $T_3$ levels ($r=0.189$, $P=0.019$ and $r=0.245$, $P=0.004$ respectively, Fig. 2). However, by multivariate regression analysis $T_3$ levels did not determine SF or PF fat independently of other confounding factors (age, gender, smoking, HOMA-IR). $T_3$ levels were also positively correlated with weight ($r=0.197$, $P=0.006$), BMI ($r=0.257$, $P=0.0004$), waist perimeter ($r=0.324$, $P<0.0001$), and WHR ($r=0.363$, $P<0.0001$). Mean $T_3$ levels and HOMA-IR were higher in subjects with PF $\geq 11$ mm compared to those with PF $<11$ mm ($T_3$ levels $1.23 \pm 0.19$ vs $1.15 \pm 0.18$, $P=0.023$ and for HOMA-IR $2.25 \pm 1.6$ vs $1.59 \pm 1.3$, $P=0.002$, $t$-test).

The $T_3/fT_4$ ratio ($T_3/fT_4$) was positively correlated with SF ($r=0.182$, $P=0.028$), waist perimeter ($r=0.217$, $P=0.003$) and the WHR ($r=0.267$, $P=0.0003$), as well as with BMI ($r=0.146$, $P=0.043$). By multivariate regression analysis, $T_3/fT_4$ was marginally associated with SF ($B=5.7$, 95% CI $-0.443$ to 11.92, $P=0.068$, $r$ square for model $=0.227$, $P$ for model $<0.001$) independently of other confounding factors (age, gender, HOMA-IR, and smoking); this association indicates that for every 0.1 change of the ratio a change of $5.7$ mm in SF is expected.

No associations were found between the titers or positivity of thyroid autoantibodies (antiTg or antiTPO) and the various measurements of adiposity such as SF, SF/PF, PF, WHR or BMI.

Finally, mean $fT_4$, $T_3$, and TSH levels did not differ between subjects fulfilling the criteria of the MS ($n=37$, 13.4%) and those who did not. Subjects with MS versus without MS: $fT_4$ 18.25 $\pm$ 3.5 vs 17.6 $\pm$ 2.3 pmol/l; TSH 1.43 $\pm$ 0.8 vs 1.57 $\pm$ 1.1 mU/l; $T_3$ 1.23 $\pm$ 0.3 vs 1.19 $\pm$ 0.2 nmol/l; all non significant.

### Discussion

In this cohort of euthyroid apparently healthy individuals, we have demonstrated, for the first time, that thyroid function parameters are associated with measurements of regional adiposity obtained by US imaging. We have shown that $fT_4$ levels are negatively associated with the abdominal SF layer thickness as well as with the SF/PF ratio. These associations were rather weak but were independent of age, sex, and other obesity parameters. Moreover, we found that TSH levels, although not independently, showed a positive association with the abdominal SF layer thickness. Thus, it

---

Table 2 Multivariate linear regression analysis for the association between subcutaneous fat layer (a) and subcutaneous/preperitoneal fat ratio (b) and parameters associated with adiposity in euthyroid individuals.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Parameter</th>
<th>Partial regression coefficient, $B$ (95% CI)</th>
<th>$t$</th>
<th>$P$</th>
<th>$r^2$</th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) Subcutaneous fat layer</td>
<td>Age</td>
<td>0.136 (0.056 to 0.217)</td>
<td>3.343</td>
<td>0.001</td>
<td>0.229</td>
</tr>
<tr>
<td></td>
<td>Gender</td>
<td>1.506 (−0.026 to 3.038)</td>
<td>1.941</td>
<td>0.054</td>
<td></td>
</tr>
<tr>
<td></td>
<td>HOMA-IR</td>
<td>5.115 (2.821 to 7.410)</td>
<td>4.401</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Smoking</td>
<td>0.709 (−0.304 to 1.722)</td>
<td>1.382</td>
<td>0.169</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Free $T_4$</td>
<td>−0.414 (−0.698 to −0.130)</td>
<td>−2.882</td>
<td>0.004</td>
<td></td>
</tr>
<tr>
<td>(b) Subcutaneous/pre-peritoneal fat ratio</td>
<td>Age</td>
<td>0.012 (0.003 to 0.021)</td>
<td>2.50</td>
<td>0.013</td>
<td>0.144</td>
</tr>
<tr>
<td></td>
<td>Gender</td>
<td>0.317 (0.140 to 0.495)</td>
<td>3.52</td>
<td>0.001</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Smoking</td>
<td>0.058 (−0.061 to 0.177)</td>
<td>0.957</td>
<td>0.340</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Free $T_4$</td>
<td>−0.051 (−0.085 to −0.018)</td>
<td>−3.041</td>
<td>0.003</td>
<td></td>
</tr>
</tbody>
</table>

*HOMA-IR was log transformed to reduce skewness.

---

www.eje-online.org
seems that subtle differences in thyroid function parameters may participate in regional adiposity even in clinically euthyroid individuals. This finding is in accordance with the report of Al-Adsani et al. who described that resting energy expenditure responds to small variations of thyroid status within the subclinical range (26).

We did not find any significant association between PF and fT₄ or TSH levels. This could be attributed to the fact that the subcutaneous compartment has an increased capacity to store fat compared to visceral fat (27). This finding is compatible with a very recent report which showed that the expression of the thyroid hormone receptor TRα1 gene is much higher in SF compared to omental fat and that this difference is much more striking in obese individuals (19). Our finding in the subgroup of overweight and obese subjects concerning the inverse association of SF layer with fT₄ levels further agrees with this report (19). Thus, it seems that the associations of slightly impaired thyroid function with components of the MS that has been reported may reflect associations with adiposity in general as this may be represented by SF (12). It thus appears that lower fT₄ levels even within the normal range may influence fat accumulation only in the subcutaneous layer, without affecting the preperitoneal layer.

Associations concerning thyroid function and regional adiposity measurements have not been previously reported; however, there are several reports in the literature which examine associations of thyroid function with other obesity parameters. fT₄ levels have been recently associated with BMI, waist perimeter and other components of the MS in both sexes (28). Two large population studies showed a positive association of TSH levels with BMI and with weight gain (5, 6) as well as a negative association between fT₄ levels and BMI (5).

In another older-population study, a similar association of TSH with BMI, over a wide range, was reported: however, only the subgroups of euthyroid and subclinically hypothyroid subjects were considered, no difference in BMI was found (29). Similarly, higher TSH levels have been found in subjects with morbid obesity compared to normal weight or mildly obese subjects (30, 31). These results point to the same direction as our findings concerning regional adiposity parameters. It is likely that the previously mentioned reports in the literature, concerning the associations of TSH or fT₄ levels with BMI in euthyroid individuals, possibly reflect associations with subtle alterations in thyroid function. In our study, we did not find associations of fT₄ or TSH levels with BMI. This could be due to the relatively smaller number of subjects studied. Similarly, there are reports in the literature where no associations between TSH or fT₄ levels and BMI were found (4, 11). However, it is likely that SF layer thickness is more sensitive than BMI as an early index of obesity.

When analysis was performed according to gender, these associations remained significant mainly in male participants. Central obesity in men is more extensive compared to women and thus these findings are probably more obvious in men than in women. Data concerning male subjects are rare in the literature. Nyrnes et al. have reported higher BMI in non-smoking euthyroid males with TSH levels in the highest quartile of the normal range compared to those in the lowest (8). In another large study TSH levels were associated with body weight in men as well as in women (6). It should be stressed that all of these studies examined rough indices of obesity and that none of them examined associations with regional fat measurements as in the current study. In the studies concerning females, as has already been mentioned, thyroid function has indeed been associated with obesity parameters (7, 10, 30).
Another interesting finding in our study concerns the positive association of T₃ levels with SF and the PF layer thickness. Moreover, T₃ levels were positively correlated with weight, BMI, waist perimeter, and WHR. There are several studies in the literature which examined associations of T₃ levels with obesity parameters. In the study by Knudsen et al. (5) no association of fT₃ levels with BMI was found. However, it is likely that in our study where the subjects were rather overweight, such association was easier to identify. Our findings are in the same direction as the study by de Pergola et al., performed in overweight and obese women where fT₃ and TSH levels were positively associated with waist perimeter (7). In particular morbidly obese subjects have been recently shown to have higher fT₃ levels compared to normal weight subjects (32). Several possible mechanisms have been proposed to explain these findings; T₃ increases energy expenditure and thermogenesis in parallel with increases in body weight (7, 33–35). Other possible explanations could be a possible resistance to the action of thyroid hormones (36) or a reset of the hypothalamic and pituitary ‘thyrostat’ (32). Leptin that is produced mainly by the SF adipocytes (37), may be also involved (10, 37).

The T₃/fT₄ ratio was also positively but not independently associated with SF thickness. This finding agrees with the report of de Pergola et al., in which the fT₃/fT₄ ratio showed a positive association with waist perimeter (7). It has been suggested that in a mild hypothyroid state where there is a slight decrease in T₄ levels, the efficiency of the conversion of T₄–T₃ by 5’-deiodinase may be increased (38). The finding of our study where fT₄ levels were negatively associated with subcutaneous abdominal adiposity might concur with these hypotheses. Thus, a variety of mechanisms may be involved in the associations of thyroid function with regional adiposity parameters.

Furthermore, we found that biochemical parameters of the MS were associated with higher TSH levels, despite the fact that associations with the presence of the MS itself were not found. These findings are partly in accordance with the results previously reported (12, 30, 39). Finally, there were no associations between the presence of thyroid autoantibodies and measurements of fat layer thickness. Similarly, no association has previously been reported between thyroid autoantibodies and BMI (11). Rotondi et al. have also reported that obese subjects with subclinical hypothyroidism, compared to normal weight ones, have a lower rate of thyroid autoantibody positivity (31).

Taken together, our results might suggest that slightly impaired thyroid function may increase regional adiposity in apparently healthy individuals. One of the limitations of our study is that it does not represent an entirely random population: the subjects included in the study volunteered to attend the preventive medicine program. These individuals might be more motivated to health problems, or they might be aware of the presence of increased risk factors. This is indeed reflected in the fact that the population sample was, on average, overweight. One cannot exclude the possibility that this is one reason why these associations were indeed revealed. It is thus possible that these associations may not apply to a population with a lower medium weight and BMI.

In conclusion, SF thickness as assessed by US is associated with lower fT₄ and higher TSH levels among slightly overweight euthyroid individuals. These findings may indicate that the reported associations of thyroid function parameters with BMI are not due to differences in visceral fat and may indeed reflect the biological significance of small variations in thyroid function for general adiposity as assessed with SF accumulation. However, one should stress that these results do not by any means justify the administration of thyroid preparations in obesity.

Declarations of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
The research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

References
1 Tourli P & Alevizaki M. Obesity and thyroid. Obesity and Metabolism 2007 3116–130.
3 Lindeman RD, Romero LJ, Schade DS, Wayne S, Baumgartner RN & Garry PJ. Impact of subclinical hypothyroidism on serum total homocysteine concentrations, the prevalence of coronary heart disease (CHD), and CHD risk factors in the New Mexico Elder Health Survey. Thyroid 2003 13595–600.


12 Roos A, Bakker SJ, Links TP, Gans RO & Wolffenbuttel BH. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. *Journal of Clinical Endocrinology and Metabolism* 2007 92 491–496.


16 Obregon MJ. Thyroid hormone and adipocyte differentiation. *Thyroid* 2008 18 185–195.


28 Kim BJ, Kim TY, Koh JM, Kim HK, Park JY, Lee KU, Shong YK & Kim WB. Relationship between serum free T₃ (rT₃) levels and metabolic syndrome (MS) and its components in healthy euthyroid subjects. *Clinical Endocrinology* 2009 70 152–160.


33 Kim B. Thyroid hormone as a determinant of energy expenditure and the basal metabolic rate. *Thyroid* 2008 18 141–144.


Received 26 May 2009
Accepted 14 June 2009

www.eje-online.org